VALERIO THERAPEUTICS Aktie

>Performance

1 Woche: 0%

1 Monat: +27,8%

3 Monate: +9,6%

6 Monate: -21,4%

1 Jahr: -34,8%

laufendes Jahr: -21,4%

>VALERIO THERAPEUTICS Aktie

Name:

VALERIO THERAPEUTICS SA

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010095596 / A0HMXA

Symbol/ Ticker:

C4X (Frankfurt)

Kürzel:

FRA:C4X, ETR:C4X, C4X:GR

Index:

Webseite:

https://valeriotx.com/

Marktkapitalisierung:

10.13 Mio. EUR

Umsatz:

1.89 Mio. EUR

EBITDA:

-16.45 Mio. EUR

Gewinn je Aktie:

-0.14 EUR

Schulden:

13.22 Mio. EUR

Liquide Mittel:

4 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

5.49 / 2.5 / -

Gewinnm./ Eigenkapitalr.:

- / -144.55%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

VALERIO THERAPEUTICS, VALERIO THERAPEUTIC

Letzte Datenerhebung:

06.07.25

>Eigentümer

Aktien: 153.97 Mio. St.

f.h. Aktien: 62.79 Mio. St.

Insider Eigner: 30.51%

Instit. Eigner: 28.6%

Leerverk. Aktien: -

>Peer Group

ADVICENNE

AELIS FARMA

AMPLITUDE SURGICAL

BOIRON

EMEIS

PHAXIAM

QUANTUM GENOMICS

SPINEGUARD

SPINEWAY

VETOQUINOL

>Chart & Kurs - Stuttgart

>Alle News

17.06.25 - 12:21	XFRA: C4X: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL VALERIO TH AC.PORT.EO-,14 C4X FR0010095596 BAW/UFN...

17.06.25 - 12:18	XFRA: INSTRUMENT_SUSPENSION - EQUBF_01 (XETRA)
	Instrument ID [5048] (C4X - FR0010095596) suspended...

19.03.25 - 12:36

Valerio Therapeutics: Report of the Board of Directors (Business Wire)

To the Ordinary and Extraordinary Shareholders' General Meeting of April 9, 2025 PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (Paris:ALVIO): Ladies and Gentlemen, We have convened this General Meeting in order to submit for your approval decisions which fall within the remit of both the Ordinary and Extraordinary General Meetings. You are therefore asked to vote on the following agenda: Agenda for the Ordinary General Meeting First resolution: Dismissal of a member of the Board of Directors (Shefali Agarwal) Second resolution: Ratification of the co-optation of a member of the Board of Directors (Jacques Mallet) Third resolution: Ratification of the co-optation of a member of the Board of Directors (Antoine Barouky) Agenda for the Extraordinary General Meeting Fourth resolution: Division of the par value of the Company's shares Fifth resolution: Amendment of Article 14 of the Company's Articles of Association Agenda for the Ordinary and Extraordinary General Meetings Sixth resolution: ...

03.03.25 - 17:39

Valerio Therapeutics Announces the Termination of the Liquidity Contract Entered Into on 29 October 2018 With KEPLER CHEUVREUX (Business Wire)

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the 'Company') announces that it has terminated the liquidity agreement entered into on 29 October 2018 with KEPLER CHEUVREUX (the 'Agreement'). The termination was effective on 19 February 2025. The termination of the Agreement was decided as part of the savings made by the Company given its cash position. The Company does not intend to enter into another liquidity contract at this stage. It should be noted that when the Agreement was signed on 29 October 2018, the following resources had been made available: - 87,612 shares; - 196,423.24 euros. At the time of the last half-yearly review of the Contract, on 31 December 2024, the following resources were included in the liquidity contract: - 486,152 shares; - 139,565.93 euros. At the close of the liquidity account, the following resources were available and returned (as at 02/19/2025): - 853,112 shares; - 114,556.17 euros. For more information, visit www...

11.10.24 - 17:54	Valerio Therapeutics Société anonyme reports 1H results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.09.24 - 22:49	Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

30.09.24 - 07:09	Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.24 - 19:27	Half-Year Liquidity Contract Statement for Valerio Therapeutics (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

05.06.24 - 07:03	Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024 (Business Wire)
	Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram